Extending the data presented here by stratifying larger patient cohorts characterised by their HER2/HER4 coexpression profile will disclose the impact of HER4 on anti-HER2 targeted HerceptinTM treatment compared with conventional therapy of HER2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.